Physician profile
Adam Link
NPI 1538519806
$1,849.84
in general payments reported to CMS, 2019-2025
27 companies · $14.89 in 2025
The $14.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $393 · 2021: $12.64 · 2022: $147 · 2023: $801 · 2024: $63.02 · 2025: $14.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $400.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $197.34 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $136.32 | 2019-2023 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.09 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $117.75 | 2020-2023 | Mounjaro, Jardiance |
| Novo Nordisk INC | $109.15 | 2019-2023 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $104.23 | 2019-2023 | Spravato |
| Bayer Healthcare Pharmaceuticals INC. | $90.62 | 2023 | |
| Pfizer INC. | $77.54 | 2020 | |
| Merck Sharp & Dohme LLC | $65.54 | 2019-2023 | Vaxneuvance, Proquad, Gardasil 9 |
| Allergan, INC. | $41.97 | 2020 | |
| Sanofi Pasteur INC. | $37.31 | 2020-2023 | |
| Amarin Pharma, INC. | $34.82 | 2019 | |
| Axsome Therapeutics, INC. | $33.63 | 2023 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $32.19 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $30.53 | 2019 | |
| Cranial Technologies, INC | $29.67 | 2020-2023 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $25.14 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.11 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.89 | 2022 | |
| Daiichi Sankyo INC. | $17.90 | 2023 | Injectafer |
| Exact Sciences Corporation | $16.99 | 2023 | Cologuard Collection Kit |
| Shire North American Group INC | $16.70 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.42 | 2022 | |
| Shield Therapeutics INC | $15.12 | 2023 | Accrufer |
| Otsuka America Pharmaceutical, INC. | $14.37 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $12.87 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.